GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (FRA:4DY) » Definitions » Asset Turnover

4d pharma (FRA:4DY) Asset Turnover : 0.01 (As of Dec. 2021)


View and export this data going back to 2020. Start your Free Trial

What is 4d pharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. 4d pharma's Revenue for the six months ended in Dec. 2021 was €0.34 Mil. 4d pharma's Total Assets for the quarter that ended in Dec. 2021 was €53.00 Mil. Therefore, 4d pharma's Asset Turnover for the quarter that ended in Dec. 2021 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. 4d pharma's annualized ROE % for the quarter that ended in Dec. 2021 was -281.66%. It is also linked to ROA % through Du Pont Formula. 4d pharma's annualized ROA % for the quarter that ended in Dec. 2021 was -159.65%.


4d pharma Asset Turnover Historical Data

The historical data trend for 4d pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Asset Turnover Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Get a 7-Day Free Trial - - 0.01 0.02 0.01

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of 4d pharma's Asset Turnover

For the Biotechnology subindustry, 4d pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4d pharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where 4d pharma's Asset Turnover falls into.



4d pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

4d pharma's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=0.614/( (39.134+50.534)/ 2 )
=0.614/44.834
=0.01

4d pharma's Asset Turnover for the quarter that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2021 )/( (Total Assets (Q: Jun. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=0.341/( (55.466+50.534)/ 2 )
=0.341/53
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


4d pharma  (FRA:4DY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

4d pharma's annulized ROE % for the quarter that ended in Dec. 2021 is

ROE %**(Q: Dec. 2021 )
=Net Income/Total Stockholders Equity
=-84.612/30.041
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-84.612 / 0.682)*(0.682 / 53)*(53/ 30.041)
=Net Margin %*Asset Turnover*Equity Multiplier
=-12406.45 %*0.0129*1.7643
=ROA %*Equity Multiplier
=-159.65 %*1.7643
=-281.66 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2021) net income data. The Revenue data used here is two times the semi-annual (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

4d pharma's annulized ROA % for the quarter that ended in Dec. 2021 is

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=-84.612/53
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-84.612 / 0.682)*(0.682 / 53)
=Net Margin %*Asset Turnover
=-12406.45 %*0.0129
=-159.65 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2021) net income data. The Revenue data used here is two times the semi-annual (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


4d pharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of 4d pharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma Headlines

No Headlines